Labcorp Holdings Inc. (LH) registered notable business activities recently. A series of high-profile acquisitions including the purchase of
CHS outreach lab assets in 13 states and selected assets of BioReference Health's innovative oncology and subsequent clinical testing services have been accomplished. Financial institutions such as Marshall Wace LLP, Franklin Resources Inc., Russell Investments Group Ltd, and Legal & General Group Plc have increased their holdings while some, including Invesco Ltd., Korea Investment CORP, Channing Capital Management LLC, have decreased their stake. Labcorp's Beta, Victor Bulto, was appointed to the board. Performance reports for Q1, Q2, and Q3 of 2025 indicate steady growth, including improved net margins and better-than-expected Q2 sales. Notably, Labcorp's
oncology diagnostics and
AI-powered pathology have potential implications for its long-term prospects. It also offers a consistent
dividend to shareholders. However, a decrease in its research unit's growth outlook persists due to biotech funding crunch.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 11 Mar 2025 07:00:00 GMT to Sat, 06 Dec 2025 11:51:47 GMT -
Rating 7
- Innovation 5
- Information 6
- Rumor 2
